Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19-Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance - 20 States, March 9, 2022-May 31, 2023
Infants aged <6 months are not eligible for COVID-19 vaccination. Vaccination during pregnancy has been associated with protection against infant COVID-19-related hospitalization. The Overcoming COVID-19 Network conducted a case-control study during March 9, 2022-May 31, 2023, to evaluate the effectiveness of maternal receipt of a COVID-19 vaccine dose (vaccine effectiveness [VE]) during pregnancy against COVID-19-related hospitalization in infants aged <6 months and a subset of infants aged <3 months. VE was calculated as (1 - adjusted odds ratio) x 100% among all infants aged <6 months and <3 months. Case-patients (infants hospitalized for COVID-19 outside of birth hospitalization and who had a positive SARS-CoV-2 test result) and control patients (infants hospitalized for COVID-19-like illness with a negative SARS-CoV-2 test result) were compared. Odds ratios were determined using multivariable logistic regression, comparing the odds of receipt of a maternal COVID-19 vaccine dose (completion of a 2-dose vaccination series or a third or higher dose) during pregnancy with maternal nonvaccination between case- and control patients. VE of maternal vaccination during pregnancy against COVID-19-related hospitalization was 35% (95% CI = 15%-51%) among infants aged <6 months and 54% (95% CI = 32%-68%) among infants aged <3 months. Intensive care unit admissions occurred in 23% of all case-patients, and invasive mechanical ventilation was more common among infants of unvaccinated (9%) compared with vaccinated mothers (1%) (p = 0.02). Maternal vaccination during pregnancy provides some protection against COVID-19-related hospitalizations among infants, particularly those aged <3 months. Expectant mothers should remain current with COVID-19 vaccination to protect themselves and their infants from hospitalization and severe outcomes associated with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
MMWR. Morbidity and mortality weekly report - 72(2023), 39 vom: 29. Sept., Seite 1057-1064 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Simeone, Regina M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 30.10.2023 Date Revised 30.10.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.15585/mmwr.mm7239a3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363671374 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363671374 | ||
| 003 | DE-627 | ||
| 005 | 20231226093841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15585/mmwr.mm7239a3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1212.xml |
| 035 | |a (DE-627)NLM363671374 | ||
| 035 | |a (NLM)37874864 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Simeone, Regina M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19-Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance - 20 States, March 9, 2022-May 31, 2023 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2023 | ||
| 500 | |a Date Revised 30.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Infants aged <6 months are not eligible for COVID-19 vaccination. Vaccination during pregnancy has been associated with protection against infant COVID-19-related hospitalization. The Overcoming COVID-19 Network conducted a case-control study during March 9, 2022-May 31, 2023, to evaluate the effectiveness of maternal receipt of a COVID-19 vaccine dose (vaccine effectiveness [VE]) during pregnancy against COVID-19-related hospitalization in infants aged <6 months and a subset of infants aged <3 months. VE was calculated as (1 - adjusted odds ratio) x 100% among all infants aged <6 months and <3 months. Case-patients (infants hospitalized for COVID-19 outside of birth hospitalization and who had a positive SARS-CoV-2 test result) and control patients (infants hospitalized for COVID-19-like illness with a negative SARS-CoV-2 test result) were compared. Odds ratios were determined using multivariable logistic regression, comparing the odds of receipt of a maternal COVID-19 vaccine dose (completion of a 2-dose vaccination series or a third or higher dose) during pregnancy with maternal nonvaccination between case- and control patients. VE of maternal vaccination during pregnancy against COVID-19-related hospitalization was 35% (95% CI = 15%-51%) among infants aged <6 months and 54% (95% CI = 32%-68%) among infants aged <3 months. Intensive care unit admissions occurred in 23% of all case-patients, and invasive mechanical ventilation was more common among infants of unvaccinated (9%) compared with vaccinated mothers (1%) (p = 0.02). Maternal vaccination during pregnancy provides some protection against COVID-19-related hospitalizations among infants, particularly those aged <3 months. Expectant mothers should remain current with COVID-19 vaccination to protect themselves and their infants from hospitalization and severe outcomes associated with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger, Stored |2 NLM | |
| 700 | 1 | |a Zambrano, Laura D |e verfasserin |4 aut | |
| 700 | 1 | |a Halasa, Natasha B |e verfasserin |4 aut | |
| 700 | 1 | |a Fleming-Dutra, Katherine E |e verfasserin |4 aut | |
| 700 | 1 | |a Newhams, Margaret M |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Orzel-Lockwood, Amber O |e verfasserin |4 aut | |
| 700 | 1 | |a Kamidani, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Pannaraj, Pia S |e verfasserin |4 aut | |
| 700 | 1 | |a Irby, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Maddux, Aline B |e verfasserin |4 aut | |
| 700 | 1 | |a Hobbs, Charlotte V |e verfasserin |4 aut | |
| 700 | 1 | |a Cameron, Melissa A |e verfasserin |4 aut | |
| 700 | 1 | |a Boom, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Sahni, Leila C |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Nofziger, Ryan A |e verfasserin |4 aut | |
| 700 | 1 | |a Schuster, Jennifer E |e verfasserin |4 aut | |
| 700 | 1 | |a Crandall, Hillary |e verfasserin |4 aut | |
| 700 | 1 | |a Hume, Janet R |e verfasserin |4 aut | |
| 700 | 1 | |a Staat, Mary A |e verfasserin |4 aut | |
| 700 | 1 | |a Mack, Elizabeth H |e verfasserin |4 aut | |
| 700 | 1 | |a Bradford, Tamara T |e verfasserin |4 aut | |
| 700 | 1 | |a Heidemann, Sabrina M |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Emily R |e verfasserin |4 aut | |
| 700 | 1 | |a Gertz, Shira J |e verfasserin |4 aut | |
| 700 | 1 | |a Bhumbra, Samina S |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Tracie C |e verfasserin |4 aut | |
| 700 | 1 | |a Bline, Katherine E |e verfasserin |4 aut | |
| 700 | 1 | |a Michelson, Kelly N |e verfasserin |4 aut | |
| 700 | 1 | |a Zinter, Matt S |e verfasserin |4 aut | |
| 700 | 1 | |a Flori, Heidi R |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Angela P |e verfasserin |4 aut | |
| 700 | 1 | |a Randolph, Adrienne G |e verfasserin |4 aut | |
| 700 | 0 | |a Overcoming COVID-19 Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Colston, Candice |e investigator |4 oth | |
| 700 | 1 | |a Kelley, Heather |e investigator |4 oth | |
| 700 | 1 | |a Murdock, Meghan |e investigator |4 oth | |
| 700 | 1 | |a Miron, Laura |e investigator |4 oth | |
| 700 | 1 | |a Sanders, Ronald C |e investigator |4 oth | |
| 700 | 1 | |a Hakimi, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Jumarang, Jaycee |e investigator |4 oth | |
| 700 | 1 | |a Mrotek, Kennis-Grace |e investigator |4 oth | |
| 700 | 1 | |a Niell, Liria Muriscot |e investigator |4 oth | |
| 700 | 1 | |a Baig, Natasha |e investigator |4 oth | |
| 700 | 1 | |a Petruccelli, Lexi |e investigator |4 oth | |
| 700 | 1 | |a Sierra, Yamila |e investigator |4 oth | |
| 700 | 1 | |a Temte, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Thayer, Imogene |e investigator |4 oth | |
| 700 | 1 | |a Zorensky, Frances |e investigator |4 oth | |
| 700 | 1 | |a Baida, Nadine |e investigator |4 oth | |
| 700 | 1 | |a Choi, Jong-Ha C |e investigator |4 oth | |
| 700 | 1 | |a Ciric, Caroline R |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Mark D |e investigator |4 oth | |
| 700 | 1 | |a Coates, Bria M |e investigator |4 oth | |
| 700 | 1 | |a Price, Heather E |e investigator |4 oth | |
| 700 | 1 | |a Stumpf, Mary |e investigator |4 oth | |
| 700 | 1 | |a Clark, Maya |e investigator |4 oth | |
| 700 | 1 | |a Dittrich, Rylie |e investigator |4 oth | |
| 700 | 1 | |a Kucukak, Suden |e investigator |4 oth | |
| 700 | 1 | |a Listerud, Eve |e investigator |4 oth | |
| 700 | 1 | |a Moran, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Drapeau, Noelle M |e investigator |4 oth | |
| 700 | 1 | |a Johnson, Brandi A |e investigator |4 oth | |
| 700 | 1 | |a Malloch, Lacy |e investigator |4 oth | |
| 700 | 1 | |a Martin, Lora |e investigator |4 oth | |
| 700 | 1 | |a Martin, Maygan |e investigator |4 oth | |
| 700 | 1 | |a Patterson, Kayla |e investigator |4 oth | |
| 700 | 1 | |a Sanders, Cameron |e investigator |4 oth | |
| 700 | 1 | |a Pruitt, Shannon |e investigator |4 oth | |
| 700 | 1 | |a Sullivan, Melissa |e investigator |4 oth | |
| 700 | 1 | |a Schwartz, Stephanie P |e investigator |4 oth | |
| 700 | 1 | |a Tomcany, Merry |e investigator |4 oth | |
| 700 | 1 | |a Rohlfs, Chelsea C |e investigator |4 oth | |
| 700 | 1 | |a Wolfe, Amber |e investigator |4 oth | |
| 700 | 1 | |a Mohammed, Fatima A |e investigator |4 oth | |
| 700 | 1 | |a Reed, J Nelson |e investigator |4 oth | |
| 700 | 1 | |a Rusler, Zachary |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Jack |e investigator |4 oth | |
| 700 | 1 | |a Wakser, Cayla |e investigator |4 oth | |
| 700 | 1 | |a Fernandez, Kailee |e investigator |4 oth | |
| 700 | 1 | |a Stewart, Laura S |e investigator |4 oth | |
| 700 | 1 | |a Abojaib, Leenah |e investigator |4 oth | |
| 700 | 1 | |a Kyles, Molly J |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t MMWR. Morbidity and mortality weekly report |d 1984 |g 72(2023), 39 vom: 29. Sept., Seite 1057-1064 |w (DE-627)NLM012594334 |x 1545-861X |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2023 |g number:39 |g day:29 |g month:09 |g pages:1057-1064 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15585/mmwr.mm7239a3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2023 |e 39 |b 29 |c 09 |h 1057-1064 | ||